


## BAY32-5915

Cat. No.:	HY-W067427		
CAS No.:	1571-30-8		
Molecular Formula:	C <sub>10</sub> H <sub>7</sub> NO <sub>3</sub>		
Molecular Weight:	189.17		
Target:	IKK		
Pathway:	NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (660.78 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	5.2863 mL	26.4313 mL	52.8625 mL
	5 mM	1.0573 mL	5.2863 mL	10.5725 mL
	10 mM	0.5286 mL	2.6431 mL	5.2863 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

Description	BAY32-5915 is a potent IKKα inhibitor with an IC <sub>50</sub> value of 60 nM. BAY32-5915 has not affect <a href="#">Doxorubicin</a> (HY-15142A)-induced NF-κB activation <sup>[1]</sup> .
IC <sub>50</sub> & Target	IKK-α 60 nM (IC <sub>50</sub> )
In Vitro	BAY32-5915 (50-200 μM) has no significant inhibitory effect on NF-κB activity in melanoma cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Pletz N, et, al. Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor. Exp Dermatol. 2012 Apr;21(4):301-4.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA